News Biogen courts controversy with $750k-a-year rare disease dru... Biogen's SMA treatment approved - but price is $125,000 per dose
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News Intercept's Ocaliva approved in EU for liver disease Potential liver blockbuster gets EU licence.
News NHS England confirms HIV prevention funding - but only via c... Large trial of HIV PrEP could lead to national programme
News AbbVie taking on Gilead with eight-week hep C course Latest combination drug resulted in 97.5% cure rates across all major disease strains
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
